Literature DB >> 23173717

Are mammographic changes in the tumor bed more pronounced after intraoperative radiotherapy for breast cancer? Subgroup analysis from a randomized trial (TARGIT-A).

Dorothee Engel1, Andreas Schnitzer, Joachim Brade, Elena Blank, Frederik Wenz, Marc Suetterlin, Stefan Schoenberg, Klaus Wasser.   

Abstract

Intraoperative radiotherapy (IORT) with low-energy x-rays is increasingly used in breast-conserving therapy (BCT). Previous non-randomized studies have observed mammographic changes in the tumor bed to be more pronounced after IORT. The purpose of this study was to reassess the postoperative changes in a randomized single-center subgroup of patients from a multicenter trial (TARGIT-A). In this subgroup (n = 48) 27 patients received BCT with IORT, 21 patients had BCT with standard whole-breast radiotherapy serving as controls. Overall 258 postoperative mammograms (median follow-up 4.3 years, range 3-8) were retrospectively evaluated by two radiologists in consensus focusing on changes in the tumor bed. Fat necroses showed to be significantly more frequent (56% versus 24%) and larger (8.7 versus 1.6 sq cm, median) after IORT than those in controls. Scar calcifications were also significantly more frequent after IORT (63% versus 19%). The high incidence of large fat necroses in our study confirms previous study findings. However, the overall higher incidence of calcifications in the tumor bed after IORT represents a new finding, requiring further attention.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 23173717     DOI: 10.1111/tbj.12049

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  9 in total

1.  Intensifying local radiotherapy for pancreatic cancer-who benefits and how do we select them?

Authors:  Sunil Krishnan; Mediha Ahmad
Journal:  J Gastrointest Oncol       Date:  2013-12

Review 2.  Intraoperative radiotherapy in early stage breast cancer: potential indications and evidence to date.

Authors:  G G Hanna; A M Kirby
Journal:  Br J Radiol       Date:  2015-03-03       Impact factor: 3.039

3.  Risk factors for seroma evacuation in breast cancer patients treated with intraoperative radiotherapy.

Authors:  Michał Falco; Bartłomiej Masojć; Magdalena Rolla; Agnieszka Czekała; Jolanta Pietruszewska; Agnieszka Rubik-Leszczyńska; Mirosław Lewocki; Magdalena Łukowiak; Andrzej Kram
Journal:  Rep Pract Oncol Radiother       Date:  2016-03-29

4.  Comparison of Mammographic Changes Across Three Different Fractionation Schedules for Early-Stage Breast Cancer.

Authors:  Sibo Tian; Lina F Paster; Sinae Kim; Laurie Kirstein; Bruce G Haffty; Adam Ferro; Judith Amorosa; Sharad Goyal
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-02-04       Impact factor: 7.038

Review 5.  Accelerated Partial Breast Irradiation in Clinical Practice.

Authors:  Frederik Wenz; Felix Sedlmayer; Carsten Herskind; Grit Welzel; Elena Sperk; Christian Neumaier; Benjamin Gauter-Fleckenstein; Jayant S Vaidya; Marc Sütterlin
Journal:  Breast Care (Basel)       Date:  2015-07-15       Impact factor: 2.860

Review 6.  Intraoperative radiotherapy for breast cancer: the lasting effects of a fleeting treatment.

Authors:  Harriet B Eldredge-Hindy; Anne L Rosenberg; Nicole L Simone
Journal:  Int J Breast Cancer       Date:  2014-08-10

Review 7.  Intraoperative Radiotherapy for Breast Cancer.

Authors:  Eleanor E R Harris; William Small
Journal:  Front Oncol       Date:  2017-12-22       Impact factor: 6.244

Review 8.  Biology of high single doses of IORT: RBE, 5 R's, and other biological aspects.

Authors:  Carsten Herskind; Lin Ma; Qi Liu; Bo Zhang; Frank Schneider; Marlon R Veldwijk; Frederik Wenz
Journal:  Radiat Oncol       Date:  2017-01-19       Impact factor: 3.481

9.  Intraoperative Radiotherapy Is Not a Better Alternative to Whole Breast Radiotherapy as a Therapeutic Option for Early-Stage Breast Cancer.

Authors:  Linwei Wang; Min Sun; Shuailong Yang; Yuanyuan Chen; Tian Li
Journal:  Front Oncol       Date:  2021-12-16       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.